Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women by Stegmann, T.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/167810
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
Frequency and characterization of known and novel RHD
variant alleles in 37 782 Dutch D-negative pregnant women
Tamara C. Stegmann,1,* Barbera
Veldhuisen,1,2,* Renate Bijman,1
Florentine F. Thurik,1 Bernadette
Bossers,2 Goedele Cheroutre,2 Remco
Jonkers,2 Peter Ligthart,2 Masja de
Haas,1,2 Lonneke Haer-Wigman1,* and
C. Ellen van der Schoot1,*
1Sanquin Research and Landsteiner Laboratory,
Academic Medical Centre, University of Amster-
dam, and 2Sanquin Diagnostic Services, Amster-
dam, The Netherlands
Received 7 October 2015; accepted for
publication 14 December 2015
Correspondence: C. E. van der Schoot,
Plesmanlaan 125, 1066CX Amsterdam, The
Netherlands.
E-mail: e.vanderschoot@sanquin.nl
*These authors contributed equally.
Summary
To guide anti-D prophylaxis, Dutch D- pregnant women are offered a
quantitative fetal-RHD-genotyping assay to determine the RHD status of
their fetus. This allowed us to determine the frequency of different mater-
nal RHD variants in 37 782 serologically D- pregnant women. A variant
allele is present in at least 096% of Dutch D- pregnant women The D-
serology could be confirmed after further serological testing in only 54% of
these women, which emphasizes the potential relevance of genotyping of
blood donors. 43 different RHD variant alleles were detected, including 15
novel alleles (11 null-, 2 partial D- and 2 DEL-alleles). Of those novel null
alleles, one allele contained a single missense mutation (RHD*443C>G) and
one allele had a single amino acid deletion (RHD*424_426del). The D- phe-
notype was confirmed by transduction of human D- erythroblasts, consoli-
dating that, for the first time, a single amino acid change or deletion
causes the D- phenotype. Transduction also confirmed the phenotypes for
the two new variant DEL-alleles (RHD*721A>C and RHD*884T>C) and
the novel partial RHD*492C>A allele. Notably, in three additional cases the
DEL phenotype was observed but sequencing of the coding sequence, flank-
ing introns and promoter region revealed an apparently wild-type RHD
allele without mutations.
Keywords: Rh blood group, RHD variant alleles, D- phenotype, blood
group genotyping.
The D antigen of the Rh blood group system is one of the most
immunogenic and complex blood group antigens (Westhoff,
2007a; Daniels & Reid, 2010). Most D- individuals lack the
complete RhD protein (Colin et al, 1991; Wagner & Flegel,
2000), which underlies its high immunogenicity. Anti-D can
cause severe haemolytic transfusion reactions and/or severe
haemolytic disease of the fetus and newborn. To prevent anti-
D formation in D- individuals, compatible D- red blood cells
(RBCs) are transfused and anti-D prophylaxis is administrated
to D- pregnant women (de Haas et al, 2015).
The Rh locus is highly polymorphic and many RHD vari-
ant alleles have been described (Flegel, 2011). One group of
RHD variant alleles, the RHD hybrid alleles, arose due to
genetic recombination between the RHD gene and the adja-
cently located RHCE gene. The second group of RHD variant
alleles carry one or multiple mutations in the RHD gene. The
genetic variation of the RHD alleles has different effects on
the level of expression of RhD protein and the number of
expressed RhD epitopes. To date, more than 60 so-called
D-null alleles have been described that cause the D- pheno-
type due to nonsense mutations, frame shift mutations, splice
site mutations or to large hybrid alleles (http://www.
uni-ulm.de/~fwagner/RH/RB2/P_RHDDnegative.htm). The
D-null alleles RHD*03N.01 and RHD*Ψ occur frequently in
the D- African population (Flegel, 2011). RHD positive hap-
lotypes are rare in D- Caucasians (Wagner et al, 2001; Flegel
et al, 2005; Chou & Westhoff, 2010). Individuals with a weak
D phenotype express the RhD protein in low quantities,
which is most often caused by mutations in the transmem-
brane regions of the RhD protein (Daniels, 2013a). Individu-
als with DEL-allele expression have an even lower amount of
the RhD protein on their RBC membrane, which can only be
detected with the very sensitive adsorption-elution technique
(Okubo et al, 1984). DEL expression is most often caused by
missense mutations causing aberrant splice sites (Reid et al,
2012). Partial D expression, in which one or more D epi-
topes are lacking, is most often caused by hybrid alleles or
due to mutations in the extracellular parts of the RhD
research paper
ª 2016 John Wiley & Sons Ltd
British Journal of Haematology, 2016, 173, 469–479
First published online 27 March 2016
doi: 10.1111/bjh.13960
protein. Some partial RHD variant alleles cause partial and
weakened expression of the D antigen (Westhoff, 2007b).
The distinction between the different variant alleles is of
importance, given that it is unlikely that individuals with
weak D or DEL expression produce allo-anti-D, in contrast
to individuals with partial D expression who are at risk of D
immunization (Daniels, 2013a; Sandler et al, 2015).
The aim of our study was to determine the frequency of
(known and novel) RHD variant alleles in the serologically
D- Dutch population. Since July 2011, Dutch D- pregnant
women have been offered a quantitative fetal-RHD-genotyp-
ing assay to guide anti-D prophylaxis. This quantitative fetal-
RHD-genotyping assay is performed with cell-free DNA iso-
lated from maternal plasma, which contains DNA of the
fetus (Scheffer et al, 2011; van der Schoot et al, 2013). How-
ever, the large majority of cell free DNA is of maternal origin
and, therefore, if a maternal RHD allele is present it will be
recognized because it results in much stronger signals in the
quantitative polymerase chain reaction (PCR) assay than
expected to arise from fetal DNA. In this paper we present
the frequency of RHD variant alleles and serological and
genetic follow up of cases identified among 37 782 screened
Dutch D- pregnant women.
Material and methods
Samples and fetal-RHD-genotyping assay
Between July 2011 and December 2012, 37 782 Dutch sero-
logically D- pregnant women (determined using two anti-D
reagents) were tested in the 27th week of pregnancy for the
presence of a D+ fetus using a quantitative fetal-RHD-geno-
typing assay. DNA was isolated from 1 ml of maternal
plasma using a DNA isolation kit (DNA and Viral NA Large
Volume Kit; Roche Holding AG, Basel, Switzerland) on a
MagNa Pure 96 Instrument (Roche) according to the manu-
facturer’s protocol. The quantitative fetal-RHD-genotyping
assay has been described previously (Scheffer et al, 2011) and
consists of a multiplexed TaqMan test, one targeting RHD
exon 5 and one targeting RHD exon 7, performed in tripli-
cate. When at least two of the three Ct values of both assays
were below 32, a maternal variant allele was suspected. When
at least two of the three Ct values of exon 7 were below 32,
but Ct values of exon 5 were either negative or above 32, a
RHD*Ψ or RHD*06 maternal variant allele was suspected. In
these cases additional genotyping and extended serology was
performed to determine whether and which variant allele was
present. Of note, the relatively frequently occurring null allele
RHD*03N.01 (Daniels et al, 1998) is not amplified and thus
not detected in this fetal-RHD-genotyping assay.
Serology
All samples were subjected to column testing on either the
Ortho Biovue Inova system (Ortho, Raritan, NJ, USA) with
an ABO D card containing anti-D monoclonal antibodies
(MoAbs) D7B8, or the Biorad/Diamed Diana system (Bio-
Rad Laboratories, Veenendaal, The Netherlands) with an
ABO DVI- card, containing anti-D MoAbs LHM59/20
(LDM3) and 175-2. Plasma of all women with a negative
result in this serological assay were tested in the fetal-RHD-
genotyping assay. A second comprehensive serological assay
was performed when a maternal variant allele was suspected.
The samples were tested with three monoclonal blend
reagents (IgM clone TH28 and IgG clone MS26) (Sanquin
Reagents, Amsterdam, The Netherlands and Immucor, Nor-
cross, GA, USA) and IgM clone D7B8, IgG clone H112196
and IgG clone LORIFA (Ortho), and one IgG clone 5C8, a
polyclonal IgG reagent (Bio-Rad Laboratories) in an immedi-
ate spin at room temperature, in a spin proceeded by 15 min
incubation at 37°C and/or by indirect antiglobulin test. If,
following this second test, the D- phenotype was suspected
and the presence of the RHD*Ψ allele was excluded, absorp-
tion-elution was performed using the Gamma ELU-KIT II
(Immucor) as per manufacturer’s protocol using a polyclonal
anti-D (Bio-Rad Laboratories) to detect a DEL allele. If the
second serological test detected a partial D variant other than
the DVI variant, the D-epitope expression of the variant
allele was determined using an in-house RhD typing kit con-
sisting of eleven monoclonal IgG antibodies and an addi-
tional six MoAbs from the ALBAclone Advanced Partial RhD
typing kit (ALBA Bioscience, Edinburgh, UK). These MoAbs
were tested in anti IgG + anti C3d gel columns (Bio-Rad
laboratories).
RH-MLPA
Maternal DNA was isolated from white blood cells using a
DNA extraction kit (QIAamp DNA Blood Mini Kit, Qiagen
Benelux, Venlo, The Netherlands). To determine RHD copy
number and the presence of RHD variant alleles, DNA sam-
ples were analysed with the RH-Multiplex Ligation-depen-
dent Probe Amplification (RH-MLPA) assay (mix p401-A1,
p402-A1 and p403-A1, MRC-Holland, Amsterdam, The
Netherlands) (Haer-Wigman et al, 2013). In some cases an
RHCE MLPA was performed using RHCE-specific probes to
determine the copies of RHCE exons 1, 3, 4, 5, 6, 7, 9 and
10 (probes listed in Table SI). One case was tested with seven
new MLPA probe combinations (targeting c.-698T, c.123A,
c.149-4875A, c.149-882G, c.244T, c.335 + 2838C and
c.1112G of RHD and RHCE) that were developed to deter-
mine the combined RHD and RHCE copy numbers of the
50UTR, exon 1, 2 and 8 and intron 1 and 2 (Table SI).
The MLPA reaction was performed according to the man-
ufacturer’s protocol on a Veriti Thermocycler (Applied
Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). A
mixture of 10 ll MLPA sample, 85 ll Hi-DiTM Formamide
(Applied Biosystems) and 05 ll GeneScanTM 500-Liz Size
Standard (Applied Biosystems) was analysed on a 3130
Genetic Analyser (Applied Biosystems). Data analysis was
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performed using Genemarker software version 1.85 (Softge-
netics, State College, PA, USA).
DNA sequencing
When indicated, all exons and intron boundaries of RHD
were sequenced and/or the promoter region of RHD was
sequenced (hg19, chr.1:g.25597899_25598887; primer
sequences are shown in Supplementary Table SI or as pub-
lished previously (Haer-Wigman et al, 2013). The PCR was
performed on a Veriti thermocycler in a total volume of
20 ll, containing 50–100 ng DNA, 10 ll of 29 GeneAmp
Fast PCR Master Mix (Applied Biosystems), 05 lmol/l for-
ward and reverse primer. PCR conditions were: 10 s at 95°C,
35 cycles of 10 s at 95°C and a specific annealing/elongation
temperature and time for each primer set ranging from 62 to
70°C, followed by 1 min at 72°C. PCR products were puri-
fied using ExoSAP-IT (GE Healthcare, Eindhoven, The
Netherlands), according to the manufacturer’s protocol. PCR
products were sequenced with ABI BigDye Terminator v3.1
kit on an ABI 3130XL sequencer (Applied Biosystems).
Heterologous transfection system
The RHD coding sequence flanked by a BamH1 and Not1
digestion site was ordered from Invitrogen (Breda, The
Netherlands) and cloned into a lentiviral vector containing
IRES-GFP for bicistronic gene expression driven under the
EF1a promoter. The c.424-426del, c.443G, c.492A, c.721C
and c.1154C mutations were mutated into the wild-type
RHD construct using QuickChange II XL Site-Directed
Mutagenesis Kit (Agilent, Amstelveen, The Netherlands)
according to the manufacturer’s protocol (Table SI). Len-
tivirus was produced by transfecting 293T cells with helper
plasmids using the Calcium Phosphate method (Sambrook &
Russel, 2001). The supernatant containing the virus particles
was then harvested for 3 days and concentrated through
ultracentrifugation. Erythroblast from five different D- (ccd-
dee) donors were cultured from peripheral blood mononu-
clear cells according to the protocol described by van den
Akker et al (2010) and kept in expansion medium for 2–3 d.
Erythroblasts were then lentivirally transduced with the RHD
wild-type construct or the different variant constructs. After
48-h transduction, cells were transferred into StemSpan med-
ium (Stem Cell technologies, Grenoble, France) supple-
mented with stem cell factor (SCF; supernatant equivalent to
100 ng/ml), erythropoietin (10 l/ml, ProSpec; East Bruns-
wick, NJ, USA), holotransferrin (05 mg/ml; Sigma-Aldrich,
Zwijndrecht, The Netherlands) and insulin (10 mg/ml;
Sigma-Aldrich) in order to allow cell differentiation (van den
Akker et al, 2010).
Cells were harvested within 5 days of differentiation and
screened for D-expression by flow cytometry using six
human monoclonal IgG anti-D of the ALBAclone Advanced
partial RhD typing kit (ALBA Bioscience), namely LHM169/
81, LHM76/59, LHM76/55, LHM169/80, LHM57/17 and
LHM76/58. Data analysis was performed with FlowJo Ver-
sion 8 software (TreeStar, Ashland, OR, USA).
To measure mRNA levels of the transduced variants, RNA
was isolated from 1 9 106 differentiated erythroblasts using
TRIzol (Life Technologies, Paisley, UK) (Chomczynski &
Sacchi, 1987) and 1 lg of RNA was used to synthesize cDNA
using random hexamers (Invitrogen). Real-time quantitative
reverse transcription PCRs (RQ-PCRs) were performed using
the reporter dye SYBR-green (Sybrgreen Mastermix, Applied
Biosystems) on a StepOnePlus (Applied Biosystems) with
RHD-specific primers as listed in Table SI.
Results
A variant RHD allele is present in 096% of Dutch D-
pregnant women
Between 2011 and 2012, the fetal-RHD-genotyping assay, to
determine whether anti-D prophylaxis is indicated, was per-
formed on a total of 37 782 D- pregnant women. In 493
women (13%) a maternal variant allele was suspected based
on Ct-values and genetic follow-up was performed in 309 of
these cases (Table SII). Genetic follow-up was not performed
in 184 cases due to (i) missing samples (n = 31); (ii) Ct-
values of around 31–32 (n = 83) and analysis in cases with
stored DNA had shown that this is virtually always due to
high fetal DNA levels and (iii) PCR results pointed to the
presence of either RHD*Ψ or RHD*06 allele, as was shown in
the first series of 159 cases with similar Ct values for exon 5
and exon 7 (Table I).
In 39 (126%) of the 309 evaluated D- pregnant women
in whom genetic follow-up was performed, the RHD negativ-
ity was based on complete deletion of the RHD gene because
the homozygous presence of the RHD*01N.01 allele was con-
firmed. In these cases the obtained Ct-values arose from high
fetal RHD-DNA concentrations.
In the remaining 270 women a variant allele was identified
(Table I). The distribution of RHD alleles in these cases was
used to calculate the distribution of RHD alleles in cases
without follow-up (Table SII). We estimate that 096% (95%
confidence interval [CI] 086–106%) of the Dutch serologi-
cally D- pregnant women had a variant allele containing
RHD exon 5 and/or 7. The most frequently detected variant
allele is the RHD*Ψ allele, which was present in 47% of the
women carrying a variant RHD allele.
Pregnant D- women determined with standard serology
carried at least 43 different variant alleles
In 218 of the 270 analysed cases carrying variant alleles and
on whom genotyping were performed, the RH-MLPA geno-
typing assay directly identified a specific known RHD variant
allele (listed in Table I). In the remaining 52 cases (as indi-
cated in Table I) additional genotyping was performed,
RHD Variant Alleles in Dutch D-Negative Pregnant Women
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Table I. RHD variant alleles detected in 270 women determined D- with standard serology.
RhD
phenotype RHD allele 1 RHD allele 2 MLPA
Number of cases
positive for genotype
D- RHD*Ψ RHD*01N.01 c 98 (2)
RHD*Ψ RHD*01N.03 c 1
RHD*Ψ RHD*03N.01 c 13
RHD*Ψ RHD*Ψ c 6
RHD*660delG RHD*01N.01 n 1
RHD*922G>T RHD*01N.01 n 2
RHD*952C>T RHD*01N.01 n 3
RHD*DEL5† RHD*01N.01 n 1
RHD*DEL8† RHD*01N.01 n 3 (1)
RHD*DEL9† RHD*01N.01 n 1
RHD*(2-10)§ RHD*01N.03 i 1
RHD*124_125del§ RHD*01N.01 n 1
RHD*335G>T§ RHD*01N.01 n 1
RHD*424_426del§ RHD*01N.01 n 1
RHD*443C>G§ RHD*01N.01 n 1
RHD*[361T>A; 380T>C; 383A>G; 455A>C;
602C>G; 667T>G; 819G>A]§
RHD*01N.01 i 1
RHD*[634 + 1T;1136T]§ RHD*01N.01 n 1
RHD*1073 + 1G>T§ RHD*01N.01 n 1
RHD*1074-1G>A§ RHD*01N.01 n 3
RHD*1084C>T§ RHD*01N.01 n 1
RHD*1174del§ RHD*01N.01 n 1
Partial RhD RHD*05.07 RHD*01N.01 c 1
RHD*06.01 RHD*01N.01 c 6
RHD*06.02 RHD*01N.01 c 40
RHD*06.02 RHD*03N.01 c 1
RHD*10.02 RHD*01N.01 i 2
RHD*11 RHD*01N.01 c 9 (1)
RHD*15 RHD*01N.01 c 12 (2)
RHD*17.02 RHD*01N.01 c 11 (4)
RHD*[178C; 689T]§ RHD*10.01 i 1
RHD*492C>A§ RHD*01N.01 c 1
DEL RHD*01EL.01 RHD*01N.01 c 9
RHD*01N.22‡ RHD*01N.01 n 1
RHD*[602C>G; 667T>G; 819G>A; 919G>A] RHD*01N.01 i 2 (1)
RHD*[602C>G; 667T>G; 819G>A; 919G>A] RHD*[602C>G; 667T>G; 819G>A; 919G>A] i 1
RHD*93_94insT RHD*01N.01 n 6
RHD*(1-9) RHD*01N.01 i 2
RHD*(1-9) RHD*Ψ i 1
RHD*1252_1253insT RHD*01N.01 n 1
RHD*721A>C§ RHD*01N.01 n 7
RHD*884T>C§ RHD*01N.01 n 1
RHD*01 RHD*01N.01 n 3
Weak RhD RHD*01W.01 RHD*01N.01 c 3
RHD*01W.02 RHD*01N.01 c 3
RHD*01W.05 RHD*01N.01 c 2
RHD*01W.22 RHD*01N.01 n 1
RHD*01W.38 RHD*01N.01 n 1
Multiplex Ligation-dependent Probe Amplification (MLPA) result: c, conclusive; i, inconclusive; n, seemingly normal RHD gene. All RHD exons
were sequenced if MLPA i or n.
(..) Cases where no extended serology could be performed.
†The literature has described that the RHD*DEL5, RHD*DEL8 and RHD*DEL9 alleles cause the DEL phenotype (Singleton et al, 2001; Flegel
et al, 2009; Reid et al, 2012); however, we detected a D- phenotype.
‡The literature indicates that RHD*01N.22 allele causes D- phenotype (Reid et al, 2012); however, we detected a DEL phenotype.
§Novel variant allele.
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because the RH-MLPA typing results were inconclusive
(n = 11) or indicated the presence of a normal RHD gene
(n = 41). Sequencing of all RHD exons revealed the presence
of previously described RHD variant alleles in 26 of these 52
cases. In the other 26 cases, 15 novel alleles were recognized
(listed in Table III), which were detected in single cases,
except for the RHD*721A>C allele, detected in seven cases,
and the RHD*1074-1G>A allele, detected in three cases
(Table I). In one case the novel RHD-RHCE-RHD allele
could only be characterized by developing an MLPA contain-
ing seven new probes. In combination with the Ccddee phe-
notype and the results of the RHCE-MLPA, it was concluded
(as explained in Fig S1) that this case most likely carries the
known RHD*01N.03 allele (described to be associated with
RhCe expression) and a novel allele in which RHD exon 1 is
deleted (RHD*(2-10)). In one other case with a partial D
expression in which the new allele could not be unambigu-
ously be proven, we assume that the known RHD*10.01 and
a novel RHD*[178A>C; 689G>T] allele are present instead of
two novel alleles (RHD*689C>T and RHD*[178A>C;
689G>T; 1136C>T]). Remarkably, in three cases, all with the
DEL phenotype and normal RhCE expression (RhCcee phe-
notype), an apparently normal wild-type RHD allele without
mutations in the coding sequence, flanking introns and pro-
moter region, was detected. In summary, a total of 43 differ-
ent RHD variant alleles, including 15 novel RHD variant
alleles, were identified in the 270 cases (Table I).
Phenotype analysis of the fifteen novel variants using
serology
Red blood cells from 259 cases (including all cases with novel
variant alleles) out of the 270 cases with a variant RHD allele
were available for additional serological analysis, including
adsorption-elution. The initial D- phenotype was confirmed
in 139 (54%) cases. In 33 (13%) cases a DEL phenotype, in
77 (30%) cases a partial D and in ten (4%) cases a weak D
phenotype was determined (Table I). The D- phenotype was
confirmed for the novel alleles: RHD*1084C>T,
RHD*124_125del and RHD*1174del (RHD*(2-10)) (RHD*
335G>T, RHD*[634+1G>T, 1136C>T], RHD*1073+1G>T
and RHD*1074-1G>A) and the novel variant composed of
the known RHD*03.03 and RHD*09.03.01 (Table III).
The novel variants RHD*884T>C and RHD*721A>C
caused the DEL phenotype (Table II). The RHD*492C>A
allele was serologically determined to lead to partial D
expression, as epitope 5 (rD7C2) and epitope 8 (HIMA-36)
were absent, whereas all other evaluated epitopes (including
epitope 8 tested with LHM76/58) were detected (Table II).
Several anti-D MoAbs were only positive in the indirect
agglutination test indicating that this variant allele has next
to partial D also weakened D expression (data not shown).
The RBC expressing the novel RHD*[178A>C; 689G>T]
allele next to the known RHD*10.01 showed loss of epitopes
1, 5 and 8. However, as this corresponds to the epitope
pattern for the RHD*10.01 allele (Wagner et al, 2002), the
exact phenotype of the new allele could not be determined
(Table II).
RhD epitope expression of the variants based on erythroblast
expression system. Of the novel variant alleles the most sur-
prising were the two variant alleles that caused the D- phe-
notype based on mutations that resulted in a single amino
acid substitution or a single amino acid deletion in trans-
membrane regions of the RhD protein (Fig S2): the
RHD*443C>G (encoding p.Thr148Arg) and RHD*424_426del
(encoding p.Met142del) alleles (Table III). We therefore
applied our novel expression system, using transduced
donor-isolated ccddee erythroblasts to confirm that the
detected mutations were indeed solely responsible for the loss
of expression. In addition, two other novel variant alleles, the
partial RHD allele RHD*492C>A and the DEL allele
RHD*721A>C were tested in this system. As a sensitivity
control, and as a control for our expression system, the
RHD*01W.02 and RHD*01 were also transduced (Fig 1).
RHD transcript levels, demonstrated that RHD mRNA levels
did not significantly differ between RHD*01 and the RHD
variants, indicating that the loss of expression was caused by
the mutation and not by differences in transduction effi-
ciency or RNA stability (Fig 2).
The erythroblast expression system confirmed the serologi-
cal findings: the RHD*443C>G and the RHD*424_426del
transcripts did not give rise to expression of any RhD epi-
tope in erythroblasts (Table II and Fig 1). The transduced
erythroblasts confirmed the partial D phenotype of the
RHD*492C>A allele, since LHM59/19 (targeting epitope 8.2)
and RD7C2 (epitope 5) were completely negative and was
not suggestive of severely weakened expression (Fig 2). The
RHD*721A>C allele (encoding p.Thr241Pro) was serologi-
cally determined to cause the DEL phenotype and this was
confirmed in erythroblast expression system, even at lower
expression levels when compared to the RHD*01W.02 allele
(Fig 1). Furthermore, only a few anti-D, LHM76/55 and
LHM169/80 (targeting epitope 3 and 6/7 respectively) were
detected as very weakly positive (Fig 1 and Table II).
Discussion
In the present study we determined that a variant RHD allele
containing RHD exon 5 and/or 7 is present in ~096% of the
Dutch D- pregnant women. Genetic follow-up determined
that almost half of the women with a variant allele carried
the RHD*Ψ variant allele and about 16% carried one of the
RHD*06 variants. All other detected RHD variants are rare
and in total we identified 43 different variant alleles, includ-
ing 15 novel RHD variant alleles. Extensive serological fol-
low-up confirmed the D- phenotype in 54% of the women,
but partial D expression was found in 29%, DEL expression
in 14% and weak D expression in 4% of the women. In three
cases we detected an apparently normal wild-type RHD allele
RHD Variant Alleles in Dutch D-Negative Pregnant Women
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yet a DEL phenotype was observed. Our analysis shows that
in 022% (95% CI 017–026%) of cases (excluding the
women carrying the RHD*06 variants) serological typing
incorrectly indicated RhD negativity. Conversely, RH-MLPA
incorrectly predicted the D+ phenotype in 005% (95% CI
003–008%) of serologically D- women.
Here we describe 15 novel alleles (11 D-null, two partial-
weak and two DEL alleles). The D- phenotype was determined
for a novel allele with a nonsense mutation (RHD*1084C>T),
two novel alleles with frame shift mutations (RHD*124_125del
or RHD*1174del), four alleles with mutations that disrupt a
splice site (RHD*335G>T, RHD*[634+1G>T, 1136C>T],
RHD*1073+1G>T and RHD*1074-1G>A) and one allele with
the deletion of exon 1 (RHD*(2-10)). The presence of this last
allele could not be unambiguously proven, because of the pres-
ence of another variant allele in this case.
The D- phenotype was also determined for a variant allele
that contained mutations of both the RHD*03.03 and
RHD*09.03 variant alleles (RHD*[361T>A; 380T>C; 383A>G;
455A>C; 602C>G; 667T>G; 819G>A]). This was unexpected
because the RHD*09.03 allele causes only a moderate weak-
ening of the RhD expression and the RHD*03.03 allele has
not been associated with an effect on RhD expression levels,
although the mutations are all found in putative transmem-
brane and intra-cellular parts of the RhD protein, which
might offer some explanation for our finding.
Interestingly, both an allele with a single missense muta-
tion RHD*443C>G (encoding p.Thr148Arg) and an allele
with the deletion of a single amino acid RHD*424_426del
(p.Met142del) cause the D- phenotype, which was confirmed
in a heterologous expression study in D- erythroblasts. Both
alleles have mutations in the fifth putative transmembrane
Fig 1. RhD expression levels of the RHD*424_426del, RHD*443C>G, RHD*492C>A and RHD*721A>C variant alleles in a heterologous expres-
sion assay. Overlay plots of the fluorescence intensity, representative for the RhD expression levels of RhD-negative erythroblasts transduced with
constructs containing the RHD*424_426del, RHD*443C>G, RHD*492C>A, or RHD*721A>C and the well-described RHD*01W.02 cDNA (black
line). The wild-type RHD*01 cDNA (black dashed line) was transduced for quantitative analysis of the expression levels. The RHD*01W.02 sensi-
tivity control showed weakened RhD expression levels compared to the RHD*01 wild-type allele. The RHD*424_426del, RHD*443C>G alleles had
completely no RhD expression, the RHD*492C>A allele had similar expression levels to the wild-type RHD*01 but showed weakened expression
of epitope 3 (LHM76/55). The RHD*721A>C showed very weak expression of epitope 3 (LHM76/55) and epitope 6/7 (LHM 169/80) weakened
RhD expression, even weaker than the RHD*01W.02 allele. Histograms are representative figures (n = 3).
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region of the RhD protein. Other RHD variant alleles with
mutations in this region, show only drastically diminished D
expression, for instance the RHD*01EL.07 (p.Ala137Glu) and
RHD*01EL.12 (p.Leu153Pro) alleles (Flegel et al, 2009; Li
et al, 2009). The mutations present in the transmembrane
region may either influence RhD binding to RhAG and
thereby disrupt the RhAG-RhD oligomer stability, or disrupt
correct protein folding (Callebaut et al, 2006).
The phenotype of the presumed novel partial RHD*
[178A>C;689G>T] allele could not be unambiguously pro-
ven, because this allele was present next to the known
RHD*10.01 allele and the observed epitope pattern (loss of
epitopes 1, 5 and 8 and weakened D expression of the other
epitopes) was similar to that described for RHD*10.01 (Wag-
ner et al, 2002). The c.689G>T mutation is responsible for
the partial weak D phenotype in the known RHD*10.01
(RHD*[689G>T;1136C>T]) allele, because the RHD*10.00
(RHD*[1136C>T]) has normal RhD expression (Wagner &
Flegel, 2002). This could mean that, for the case carrying the
RHD*10.01 allele and the RHD*[178A>C;689G>T], the
RHD*10.01 allele alone is responsible for this partial weak D
phenotype but it is possible that the novel RHD*
[178A>C;689G>T] variant results in a similar phenotype as
both variants carry the c.689G>T (p.Ser230Ile) mutation.
The novel variant allele RHD*492C>A (p.Asp164Glu)
equally caused partial weak D expression on RBCs and, also
in the heterologous expression system, epitope 5 and part of
epitope 8 were absent.
The novel RHD*721A>C allele (p.Thr241Pro) and
RHD*884T>C (p.Met295Thr) with a single missense muta-
tion in the transmembrane region of the RhD protein causes
the DEL phenotype. Interestingly, the RHD*721A>C allele
was detected in seven cases whereas all other novel alleles,
except the RHD*1074-1G>A allele, were detected in single
cases. This allele was not detected in previous studies per-
formed in Germany, Austria, Poland and Belgium, respec-
tively (Flegel et al, 2009; Polin et al, 2009; Orzinska et al,
2013; Van Sandt et al, 2015, respectively, indicating that this
allele is specific for the Dutch population. All women posi-
tive for the RHD*721A>C allele had Dutch surnames but we
have no indication that these women are related.
The DEL and RhCcee phenotype was detected in three
cases with a wild-type RHD*01 allele and without any muta-
tion in the intron boundaries or in the promoter region of
the RHD gene. The RhCe expression was normal in these
two cases. Flegel et al (2009) also described a single case
without mutations in the RHD exons and intron boundaries
with the DEL and a normal RhCe phenotype. Possibly, in
these cases a deep intronic mutation is present or a gene that
is required for membrane expression of the RhD protein is
mutated.
Furthermore, it is important to note that for the variants
RHD*DEL5, RHD*DEL8, RHD*DEL9, RHD*01N.22, the D-
phenotype determined in this study deviated from previously
reported DEL phenotypes (Singleton et al, 2001; Flegel et al,
2009; Reid et al, 2012). A D- phenotype for RHD*DEL8 and
RHD*DEL9 has been described (Wagner et al, 2001) and for
RHD*DEL8, Kormoczi et al (2005) described a partial D phe-
notype. Moreover, in agreement with our observed D- serology
is the fact that alloimmunization has occurred in individuals
carrying the RHD*DEL8 (Kormoczi et al, 2005; Gardener et al,
2012) or the RHD*DEL5 (Daniels & Reid, 2010) allele.
Three large studies have been performed (46 133 D-
donors in Germany (Flegel et al, 2009), 31 200 D- donors in
Poland (Orzinska et al, 2013) and 23 330 D- donors Austria
(Polin et al, 2009)) to ascertain the presence of RHD variant
alleles in D- donors, in which considerably lower percentages
of D- donors carried RHD variant alleles, 021%, 020% and
040%, respectively. The African RHD*Ψ allele was observed
at low frequency (003%) in the German donor population
(Flegel et al, 2009) and not among the Austrian and Polish
donors (Polin et al, 2009; Orzinska et al, 2013). Furthermore,
in our study the RHD*06 variant was tested as D- on pur-
pose, while this was not the case in other studies. Even if the
frequency of variant alleles in our study is recalculated
excluding the RHD*Ψ and the RHD*06 alleles, 032% (95%
CI 026–037%) of the D- women carry an RHD variant: this
is still slightly higher than the frequency in the two largest
blood donor studies, possibly reflecting the multiracial origin
of the Dutch pregnant population.
In conclusion, 096% of the Dutch D- pregnant women
carry a D variant allele harbouring RHD exon 5 and/or exon
7. The large majority of pregnant women with a variant allele
carry an RH-null allele or partial RHD allele and need
administration of anti-D prophylaxis to prevent anti-D
immunization. Genotyping of this group of women has the
Fig 2. RhD-transcript levels of D- transduced erythroblasts with the
novel variants: RHD*424_426del, RHD*443C>G, RHD*492C>A and
RHD*721A>C. Transcript levels of the various RHD mRNA show no
significant differences between the novel variants or our sensitivity
controls (RHD*01, RHD*01W.02) indicating that the fluorescence-
activated cell sorting results do not depend on different levels of viral
transduction. Each dot represents one D-negative erythroblast donor.
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limited advantage in that the woman with weak D type 1, 2
and 3 are recognized and can be regarded in the current and
any subsequent pregnancy as D+. More importantly, our
study emphasizes the relevance of genotyping of blood
donors (Denomme, 2013; Sandler et al, 2015). Furthermore,
this cohort of extensively typed D- women can be used to
optimize RHD genotyping assays, as it is essential that the
most frequently occurring D-null alleles are identified for
correct prediction of the D phenotype via a genotyping assay
(Gassner et al, 2005; Daniels, 2013b).
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